share_log

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock

數字背後:7位分析師討論 Zevra Therapeutics 股票
Benzinga ·  09/25 01:01
7 analysts have expressed a variety of opinions on Zevra Therapeutics (NASDAQ:ZVRA) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度裏,有7位分析師對Zevra Therapeutics (NASDAQ:ZVRA)發表了各種不同的意見,從看好到看淡不一。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析師最近的評級概述,爲了全面了解過去30天的情緒變化並與前幾個月進行比較,提供了深入的見解。
Analysts have set 12-month price targets for Zevra Therapeutics, revealing an average target of $19.71, a high estimate of $25.00, and a low estimate of $15.00. This current average reflects an increase of 8.48% from the previous average price target of $18.17.
分析師們爲Zevra Therapeutics設定了12個月的目標價格,顯示平均目標爲19.71美元,最高估價爲25.00美元,最低估價爲15.00美元。當前的平均目標反映了與之前的平均目標價格18.17美元相比的8.48%的增長。
Exploring Analyst Ratings: An...
分析師評...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論